Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | SLC9A1 | P19634 | 8/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.42 |
| ▸ | TDO2 | P48775 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.40 |
| ▸ | OGFRL1 | Q5TC84 | 2/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1177265 | 0.76 | TDP1 (0.46) | OPRM1OPRK1OGFRL1OPRD1OPRL1 | |
| SCHEMBL2475745 | 0.76 | TDP1 (0.46) | OPRM1OPRK1OGFRL1OPRD1OPRL1 | |
| SCHEMBL14578738 | 0.74 | CYP2D6 (0.55) | CYP2D6SLC9A1GRM2NPC1MAPT | |
| SCHEMBL4288610 | 0.72 | GAA (0.47) | SLC9A1GRM2NPC1MAPTRAB9A | |
| SCHEMBL10625058 | 0.71 | TDO2 (0.59) | SLC9A1GRM2TDO2NPC1MAPT | |
| SCHEMBL10002325 | 0.70 | GRM2 (0.58) | CYP2D6SLC9A1GRM2TDO2NPC1 | |
| SCHEMBL730354 | 0.69 | SLC9A1 (0.66) | CYP2D6SLC9A1GRM2NPC1MAPT | |
| SCHEMBL10606015 | 0.69 | TDO2 (0.60) | CYP2D6SLC9A1GRM2TDO2NPC1 | |
| SCHEMBL13240370 | 0.68 | GRM2 (0.60) | SLC9A1GRM2TDO2NPC1MAPT | |
| SCHEMBL29479909 | 0.67 | SLC9A1 (0.67) | CYP2D6SLC9A1GRM2NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1881827-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2011-09-28 | — | — | EP | disclosed |
| US-7888344-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2011-02-15 | — | — | US | disclosed |
| US-20080306060-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306060-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | MAP4K2, PDPK1, DAPK2 | CYP2D6 2006/4885SLC9A1 4737/4885GRM2 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.